All In Biotech

NDA 021876 · Duchesnay

Diclegis

Doxylamine Succinate, Pyridoxine Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Oct 31, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Apr 8, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

18

5 Phase 3, 0 recruiting

FAERS reports

409

211 serious, 11 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 3, 2025.

Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Limitations of Use Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets have not been studied in women with hyperemesis gravidarum. Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are a fixed dose combination drug product of doxylamine succinate, an antihistamine, and pyridoxine hydrochloride, a Vitamin B6 analog, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. ( 1 )

Mechanism: The mechanism of action of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • DICLEGIS · DOXYLAMINE SUCCINATE 10MG; PYRIDOXINE HYDROCHLORIDE 10MG · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Doxylamine" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • maternal exposure during pregnancy50
  • premature delivery43
  • exposure during pregnancy40
  • foetal exposure during pregnancy36
  • nausea33
  • somnolence32
  • vomiting31
  • drug ineffective24
  • off label use22
  • abortion spontaneous21
  • headache20
  • dizziness13

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20133
20146
201531
201667
201777
201876
201941
202026
202115
202211
202316
202411
202519
202610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Diclegis (Doxylamine Succinate/Vit B6)

2024 spending

$8K

Beneficiaries

30

36 claims

Per beneficiary

$270

$3.58 per unit

View as table
YearSpending
2020$61,425
2021$24,538
2022$18,817
2023$17,080
2024$8,109

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 47 on PubMed

Sponsor: Duchesnay

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.